Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis

References

• Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association, Arlington, VA. 2010. Available at: http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx. Accessed February 1, 2012
   Google Scholar
• Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-47
   PubMed Web of Science ®Google Scholar
• Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr 2008;13:27-33
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41
   PubMed Web of Science ®Google Scholar
• Tran PV, Bymaster FP, McNamara RK, et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003;23:78-86
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah R, Cantillon M, et al. Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions. J Womens Health (Larchmt) 2005;14:609-16
   PubMed Web of Science ®Google Scholar
• Thase ME. Are SNRIs more effective than SSRIs? A review of the current state of the controversy. Psychopharmacol Bull 2008;41:5-85
   PubMedGoogle Scholar
• Bradley AJ, Lenox-Smith AJ. Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. J Psychopharmacol 2013;27:740-58
   PubMed Web of Science ®Google Scholar
• Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry 2003;64(Suppl 13):5-12
   PubMedGoogle Scholar
• Richelson E. The pharmacology of antidepressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994;55(Suppl A):34-9
   PubMed Web of Science ®Google Scholar
• Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol 2013;3:151-61
   PubMedGoogle Scholar
• Warrington SJ, Padgham C, Lader M. The cardiovascular effects of antidepressants. Psychol Med Monogr Suppl 1989;16:i-40
   PubMedGoogle Scholar
• Glassman AH. Cardiovascular effects of antidepressant drugs: updated. J Clin Psychiatry 1998;59(Suppl 15):13-18
   PubMedGoogle Scholar
• Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2014
   Google Scholar
• Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014
   Google Scholar
• Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc, 2013
   Google Scholar
• Fetzima [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc., 2013
   Google Scholar
• Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-8
   PubMed Web of Science ®Google Scholar
• Deecher DC, Beyer CE, Johnston G, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 2006;318:657-65
   PubMed Web of Science ®Google Scholar
• Pristiq [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc., 2013
   Google Scholar
• Septien-Velez L, Pitrosky B, Padmanabhan SK, et al. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 2007;22:338-47
   PubMed Web of Science ®Google Scholar
• DeMartinis NA, Yeung PP, Entsuah R, et al. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 2007;68:677-88
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Manley AL, Padmanabhan SK, et al. Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 2008;24:1877-90
   PubMed Web of Science ®Google Scholar
• Boyer P, Montgomery S, Lepola U, et al. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 2008;23:243-53
   PubMed Web of Science ®Google Scholar
• Tourian KA, Padmanabhan SK, Groark J, et al. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31:1405-23
   PubMed Web of Science ®Google Scholar
• Iwata N, Tourian KA, Hwang E, et al. Efficacy and safety of desvenlafaxine 25 and 50 mg/day in a randomized, placebo-controlled study of depressed outpatients. J Psychiatr Pract 2013;19:5-14
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Tourian KA, Hwang E, et al. A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/d in adult outpatients with major depressive disorder. BMC Psychiatry 2013;13:94
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 2013;74:1010-7
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Reddy S, Yang L, et al. Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 2011;31:569-76
   PubMed Web of Science ®Google Scholar
• Clayton A, Tourian KA, Focht K, et al. Desvenlafaxine 50- and 100-mg/d vs placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial. J Clin Psychiatry 2014; [published online ahead of print October 28, 2014]. doi:10.4088/JCP.13m08978
   Google Scholar
• Rickels K, Montgomery SA, Tourian KA, et al. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. J Clin Psychopharmacol 2010;30:18-24
   PubMed Web of Science ®Google Scholar
• Rosenthal JZ, Boyer P, Vialet C, et al. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder: a randomized controlled trial. J Clin Psychiatry 2013;74:158-66
   PubMed Web of Science ®Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
   PubMed Web of Science ®Google Scholar
• Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, 1976:217-22
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV. 4th ed. Washington, DC: American Psychiatric Publishing, 1994
   Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Publishing, 2000
   Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507-20
   PubMed Web of Science ®Google Scholar
• Thase ME, Kornstein SG, Germain JM, et al. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14:144-54
   PubMed Web of Science ®Google Scholar
• Clayton AH, Kornstein SG, Rosas G, et al. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr 2009;14:183-95
   PubMed Web of Science ®Google Scholar
• Pae CU. Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2923-8
   PubMed Web of Science ®Google Scholar
• Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009;117(Suppl 1):S26-S43
   PubMed Web of Science ®Google Scholar
• Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005;25:132-40
   PubMed Web of Science ®Google Scholar
• Citrome L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant–what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2013;67:1089-104
   PubMed Web of Science ®Google Scholar
• Sambunaris A, Bose A, Gommoll CP, et al. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol 2014;34:47-56
   PubMed Web of Science ®Google Scholar
• Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007;30:437-55
   PubMed Web of Science ®Google Scholar